This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Sanofi branded clouded background image

Latest Education

Education23 May 2024

Vaccines Eco-pack Recycling

Sohail Akhtar - 29.03.24

Education17 Apr 2024

Diabetes UK 2024: Connecting the Dots: Benefits of pen connectivity for people living with diabetes

Slides and recording of Diabetes UK 2024 - in collaboration with Diabetes Specialist Nurse Forum UK

Sohail Akhtar - 29.03.24

Education17 Apr 2024

Diabetes UK 2024: Sustainably scripting tomorrow with Sanofi's Planet Cares Programme and Pen Recycling pilot

Slides and recording of Diabetes UK 2024 - in collaboration with Diabetes Specialist Nurse Forum UK

Education23 Oct 2023

The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Education23 Oct 2023

What Insulins Do I Need In My Toolbox To Support People With Type 2 Diabetes

Lantus® (insulin glargine 100 units/mL) Prescribing Information UK Toujeo® (insulin glargine 300 units/mL) Prescribing Information UK

Education23 Oct 2023

Implementing Artificial Intelligence to Risk Stratify, Manage and Refer Patients

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Education23 Oct 2023

New Approaches and Innovation in Lipid Services – Strengthening the Relationship between Primary and Secondary Care

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Education23 Oct 2023

What the InRange Study Can Teach Us About Time-In-Range (TIR)

Toujeo® (insulin glargine 300 units/mL) Prescribing Information

Education23 Oct 2023

Strengthening the Interface Between Primary and Secondary Care

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

MAT-XU-2305049 (v2.0) Date of preparation: February 2024

Therapeutic Areas
- Dermatology
  - Atopic Dermatitis
- Respiratory
  - Asthma
  - COPD
- Cardiology
  - Dyslipidaemia
  - Thrombosis
- Other Topics
  - Payor
  - General Topics
- Rare Disease
  - Pompe
  - Gaucher
  - Better Care for Rare
  - Fabry
- Vaccines
  - Other Vaccines Topics
  - Influenza
- Diabetes
  - Type 1 Diabetes
  - Type 2 Diabetes
- Transplant
  - Transplant
- Oncology
  - Multiple Myeloma
  - Other Oncology Topics
- Neurology
  - Multiple Sclerosis
Articles
- Rare Disease
  - Better Care for Rare
  - Gaucher
  - Pompe
  - Fabry
- Diabetes
  - Type 2 Diabetes
  - Type 1 Diabetes
- Respiratory
  - COPD
  - Asthma
- Cardiology
  - Dyslipidaemia
  - Thrombosis
- Oncology
  - Multiple Myeloma
  - Other Oncology Topics
- Transplant
  - Transplant
- Other Topics
  - General Topics
- Vaccines
  - Influenza
- Neurology
  - Multiple Sclerosis
- Dermatology
  - Atopic Dermatitis
Resources
- Cardiology
  - Dyslipidaemia
- Other Topics
  - Payor
- Rare Disease
  - Pompe
  - Gaucher
- Respiratory
  - Asthma
- Dermatology
  - Atopic Dermatitis
- Vaccines
  - Other Vaccines Topics
  - Influenza
- Diabetes
  - Type 1 Diabetes
Tools
- Dermatology
  - Atopic Dermatitis
- Respiratory
  - Asthma
Events
- Vaccines
  - Other Vaccines Topics
- Diabetes
  - Type 2 Diabetes
Education
- Vaccines
  - Other Vaccines Topics
- Diabetes
  - Type 1 Diabetes
  - Type 2 Diabetes
- Cardiology
  - Dyslipidaemia
- Transplant
  - Transplant
Products